Schmiedt Chad W, Lu Yan, Heaney Kathleen, Muir Peter, Amodie Deborah M, Markel Mark D
Comparative Orthopaedic Research Laboratory, Department of Surgical Sciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI 53706-1100, USA.
Am J Vet Res. 2007 Aug;68(8):834-40. doi: 10.2460/ajvr.68.8.834.
To determine the effects of 2 doses of recombinant human bone morphogenetic protein-2 in an absorbable collagen sponge (rhBMP-2/ACS) on bone healing in dogs.
27 adult dogs.
Dogs underwent a mid-diaphyseal (1-mm) tibial osteotomy (stabilized with external skeletal fixation) and received an ACS containing 0.28 mg (0.2 mg/mL) or 0.56 mg (0.4 mg/mL) of rhBMP-2 or no treatment (control dogs). All dogs were examined daily; bone healing was assessed via radiography and subjective lameness evaluation every 2 weeks. After euthanasia at 8 weeks, tibiae were evaluated biomechanically and histologically.
Control dogs required antimicrobial treatment for pin-site-related complications more frequently than did rhBMP-2/ACS-treated dogs. At 4 and 6 weeks, weight bearing was greater in dogs treated with rhBMP-2/ACS (0.2 mg/mL) than in control dogs, albeit not significantly. Compared with control treatment, both doses of rhBMP-2/ACS accelerated osteotomy healing at 4, 6, and 8 weeks, and the 0.2 mg/mL dose enhanced healing at 2 weeks; healing at 6 weeks was greater for the lower-dose treatment than for the higher-dose treatment. Histologically, healing at 8 weeks was significantly improved for both rhBMP-2/ACS treatments, compared with control treatment. Among groups, biomechanical variables did not differ, although less osteotomy-site failures occurred in rhBMP-2/ACS-treated groups.
In dogs that underwent tibial osteotomy, rhBMP-2/ACS (0.2 mg/mL) appeared to accelerate bone healing and reduce lameness (compared with control treatment) and apparently augmented bone healing more than rhBMP-2/ACS (0.4 mg/mL). Compared with control dogs, rhBMP-2/ACS-treated dogs required antimicrobial treatments less frequently.
确定两种剂量的重组人骨形态发生蛋白-2负载于可吸收胶原海绵(rhBMP-2/ACS)对犬骨愈合的影响。
27只成年犬。
犬接受胫骨骨干中部(1毫米)截骨术(采用外骨骼固定稳定),并接受含0.28毫克(0.2毫克/毫升)或0.56毫克(0.4毫克/毫升)rhBMP-2的ACS治疗,或不接受治疗(对照犬)。所有犬每天接受检查;每2周通过X线摄影和主观跛行评估来评估骨愈合情况。在8周时实施安乐死后,对胫骨进行生物力学和组织学评估。
对照犬因针道相关并发症而需要抗菌治疗的频率高于接受rhBMP-2/ACS治疗的犬。在4周和6周时,接受rhBMP-2/ACS(0.2毫克/毫升)治疗的犬负重比对照犬更大,尽管差异不显著。与对照治疗相比,两种剂量的rhBMP-2/ACS在4周、6周和8周时均加速了截骨愈合,0.2毫克/毫升剂量在2周时促进了愈合;低剂量治疗在6周时的愈合情况优于高剂量治疗。组织学上,与对照治疗相比,两种rhBMP-2/ACS治疗在8周时的愈合均有显著改善。在各治疗组之间,生物力学变量无差异,尽管rhBMP-2/ACS治疗组的截骨部位失败情况较少。
在接受胫骨截骨术的犬中,rhBMP-2/ACS(0.2毫克/毫升)似乎加速了骨愈合并减轻了跛行(与对照治疗相比),且明显比rhBMP-2/ACS(0.4毫克/毫升)更能增强骨愈合。与对照犬相比,接受rhBMP-2/ACS治疗的犬需要抗菌治疗的频率更低。